Brind.
  1. Silo Pharma and Hoth Therapeutics formed a joint venture, leveraging Hoth's successful antisense therapy targeting KIT for GIST.

Jasper Therapeutics develops briquilimab, a new drug candidate targeting KIT, in collaboration with Karlsruhe Institute of Technology.

4 reports, 1 independent Updated Aug 28
Gone quiet
Reports
4
Developments
3
Repetition
25%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Jasper Therapeutics develops briquilimab, a new drug candidate targeting KIT, in collaboration with Karlsruhe Institute of Technology.

Who's involved

What this event is mainly about
Karlsruhe Institute of Technology

How it developed

Newest first. Tap a step to see who reported it.
  1. Jasper Therapeutics develops briquilimab targeting KIT, related to KIT research at Karlsruhe Institute of Technology.1 source
  2. Jasper Therapeutics restructured and changed CMOs while advancing the BEACON study for briquilimab.
  3. Jasper Therapeutics targets KIT (CD117) for mast cell driven diseases.

Keep exploring

Part of

Silo Pharma and Hoth Therapeutics formed a joint venture, leveraging Hoth's successful antisense therapy targeting KIT for GIST. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireJasper Therapeutics to Present at Upcoming Investor Conferences REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnolo
  • GlobeNewswireJasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jaspe
  • Unknown outlet
  • Unknown outlet